The AI-powered qCT LN Quant software reportedly generates 2D and 3D reconstructions and facilitates assessment of morphologic data across multiple thoracic studies.
Offering advanced quantitative evaluation of solid lung nodules, the artificial intelligence (AI)-powered software qCT LN Quant has garnered 510(k) clearance from the Food and Drug Administration (FDA).
In addition to providing short-axis, long-axis and average diameter measurements of lung nodules, the qCT LN Quant software enables radiologists to determine estimated volume doubling time and assess nodule tracking for multiple thoracic studies, according to Qure.ai, the developer of qCT LN Quant.
The newly FDA-cleared qCT LN Quant software enables radiologists to determine estimated volume doubling time and assess nodule tracking for multiple thoracic studies, according to Qure.ai, the developer of qCT LN Quant. (Image courtesy of Qure.ai.)
The company also points out that qCT LN Quant provides Brock malignancy risk scoring, 2D and 3D image reconstructions and management suggestions based on Fleischner Society guidelines.
“(qCT LN Quant is) the next stage solution in the AI-optimized patient pathway to evaluate lung nodules on at-risk patient CT scans, giving precise quantitative characterization, plus tracking volumetric growth over time,” noted Bhargava Reddy, the chief business officer of oncology at Qure.ai.
In regard to reimbursement for use of qCT LN Quant, Qure.ai said the software is “potentially eligible” for the 3D reconstruction CPT code as well as the CPT 0722T code for tissue quantification.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
FDA Clears Ultrasound AI Detection for Pleural Effusion and Consolidation
June 18th 2025The 14th FDA-cleared AI software embedded in the Exo Iris ultrasound device reportedly enables automated detection of key pulmonary findings that may facilitate detection of pneumonia and tuberculosis in seconds.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.